Differential Benefit from Fractionated Dose-Dense First-Line Chemotherapy for Epithelial Ovarian Cancer (EOC) According to Kelim-Evaluated Tumour Primary Chemosensitivity: Exploratory Analysis of Icon-8 Trial (2022)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.2139/ssrn.4043678
Publication URI: http://dx.doi.org/10.2139/ssrn.4043678
Type: Journal Article/Review
Parent Publication: SSRN Electronic Journal